Can CSF biomarkers predict future MS disease activity and severity

Volume: 26, Issue: 5, Pages: 582 - 590
Published: Jan 22, 2020
Abstract
Multiple sclerosis (MS) is a heterogeneous disease. With several disease modifying treatments of different mechanisms of action in use now and in development, it is important to identify reliable biomarkers to identify those higher risk MS patients in whom stronger but riskier treatments might be used, as well as to identify those for whom safer treatments of lower efficacy would be sufficient. Here we review cerebrospinal fluid (CSF) and blood...
Paper Details
Title
Can CSF biomarkers predict future MS disease activity and severity
Published Date
Jan 22, 2020
Volume
26
Issue
5
Pages
582 - 590
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.